Literature DB >> 11205134

cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease.

S Mandel1, E Grünblatt, M Youdim.   

Abstract

cDNA microarray membranes comprising 1,200 different gene fragments have been employed to identify gene expression profile in MPTP-induced nigro striatal dopamine neurodegeneration and its protection with Rapomorphine. Both MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and R-apomorphine (R-APO) induced alterations in specific patterns of gene expression. MPTP altered the expression of 49 different genes involved in oxidative stress (oxidative stress-induced protein A 170, cytochrome P450 1A1 and Osp94), inflammation (cytotoxic cytokines, eg: IL-1, IL-6, TNF-alpha), protective cytokines (IL-10), glutamate receptors (NMDA but not AMPA receptors), neurotrophic factors (GDNF, EGF), nitric oxide synthase and transferrin receptor, as determined by microarray membrane hybridization. Furthermore, an additional cascade of further, yet undefined events, also occurred (cell cycle regulators and signal transduction factors), that might act in parallel to oxidative stress (OS) and inflammation, to converge eventually into a common pathway leading to neurodegeneration. R-APO, previously shown by us to protect against MPTP neurotoxicity, prevented the over expression of several genes known to participate in cell death. cDNA microarrays will provide new prospects to study and identify various mechanism of neurodegeneration and neuroprotection not feasible with conventional biochemical procedures, as well as new prospects to develop effective neuroprotective drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205134     DOI: 10.1007/978-3-7091-6301-6_7

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  16 in total

1.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

2.  Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

Authors:  Silvia Mandel; Edna Grünblatt; Gila Maor; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 3.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

4.  IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration.

Authors:  Björn Spittau; Xiaolai Zhou; Ming Ming; Kerstin Krieglstein
Journal:  Neuromolecular Med       Date:  2012-07-08       Impact factor: 3.843

Review 5.  Gender differences in neurological disease: role of estrogens and cytokines.

Authors:  Anna Członkowska; Agnieszka Ciesielska; Grazyna Gromadzka; Iwona Kurkowska-Jastrzebska
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

6.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

Review 7.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

8.  Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Silvia Mandel; Gila Maor; Moussa B H Youdim
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.